Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals

Horibe,Hideki; Ueyama,Chikara; Fujimaki,Tetsuo; Oguri,Mitsutoshi; Kato,Kimihiko; Ichihara,Sahoko; Yamada,Yoshiji

doi:10.3892/mmr.2014.1902

Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals

Authors:
- Hideki Horibe
- Chikara Ueyama
- Tetsuo Fujimaki
- Mitsutoshi Oguri
- Kimihiko Kato
- Sahoko Ichihara
- Yoshiji Yamada
View Affiliations

Affiliations: Department of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Gifu 507-8522, Japan, Department of Cardiovascular Medicine, Inabe General Hospital, Inabe, Mie 511-0428, Japan, Department of Cardiology, Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi 453-0046, Japan, Department of Internal Medicine, Meitoh Hospital, Nagoya, Aichi 465-0025, Japan, Department of Human Functional Genomics, Life Science Research Center, Mie University, Tsu, Mie 514-8507, Japan
Published online on: January 16, 2014 https://doi.org/10.3892/mmr.2014.1902
Pages: 808-812

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We have previously shown that the C→T polymorphism (rs6929846) of the butyrophilin, subfamily 2, member A1 gene (BTN2A1) was significantly associated with myocardial infarction. Considering that dyslipidemia is a significant risk factor for coronary heart disease, it was hypothesized that the association between rs6929846 of BTN2A1 and myocardial infarction may be attributable, at least in part, to its effect on the susceptibility to dyslipidemia. The purpose of the present study was to examine a possible association of rs6929846 of BTN2A1 with dyslipidemia in community‑dwelling individuals. The study subjects were comprised of 5,958 community‑dwelling individuals (2,909 subjects with dyslipidemia and 3,049 controls) who were recruited into a population‑based cohort study in Inabe, Japan. Dyslipidemia was defined by a serum concentration of triglycerides of ≥1.65 mmol/l, a serum high‑density lipoprotein‑cholesterol concentration of <1.04 mmol/l or a serum low‑density lipoprotein (LDL)‑cholesterol concentration of ≥3.64 mmol/l. A comparison of the allele frequencies or genotype distributions by the χ2 test revealed that rs6929846 of BTN2A1 was significantly associated with dyslipidemia (P<0.05). A multivariable logistic regression analysis adjusted for age, gender, body mass index, smoking status and the prevalence of diabetes mellitus revealed that rs6929846 of BTN2A1 was significantly (dominant model; P=2.4x10-4; odds ratio, 1.29) associated with dyslipidemia, with the minor T allele representing a risk for this condition. Among all the individuals, the serum concentrations of total cholesterol, triglycerides and LDL‑cholesterol were significantly greater for individuals in the combined CT and TT genotype groups than for those with the CC genotype. BTN2A1 may thus be a susceptibility gene for dyslipidemia in community‑dwelling individuals.

View Figures

View References

1	Khera AV and Rader DJ: Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics. Trends Cardiovasc Med. 19:195–201. 2009. View Article : Google Scholar : PubMed/NCBI
2	Ordovas JM: Nutrigenetics, plasma lipids, and cardiovascular risk. J Am Diet Assoc. 106:1074–1081. 2006. View Article : Google Scholar : PubMed/NCBI
3	Stamler J, Wentworth D and Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:2823–2828. 1986. View Article : Google Scholar
4	Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM and Tyroler HA: Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 322:1700–1707. 1990.PubMed/NCBI
5	Aulchenko YS, Ripatti S, Lindqvist I, et al: Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 41:47–55. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kathiresan S, Melander O, Guiducci C, et al: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 40:189–197. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kathiresan S, Willer CJ, Peloso GM, et al: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 41:56–65. 2009. View Article : Google Scholar : PubMed/NCBI
8	Yamada Y, Nishida T, Ichihara S, et al: Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. Atherosclerosis. 215:145–152. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yamada Y, Matsuo H, Warita S, et al: Prediction of genetic risk for dyslipidemia. Genomics. 90:551–558. 2007. View Article : Google Scholar : PubMed/NCBI
10	Itoh Y, Mizuki N, Shimada T, et al: High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics. 57:717–729. 2005. View Article : Google Scholar : PubMed/NCBI
11	Smith DG: Epidemiology of dyslipidemia and economic burden on the healthcare system. Am J Manag Care. 13(Suppl 3): S68–S71. 2007.PubMed/NCBI
12	World Health Organization. Quantifying selected major risks to health. The World Health Report 2002 - Reducting Risks, Promoting Healthy Life. World Health Organization; Geneva: pp. 47–97. 2002
13	Fujimaki T, Kato K, Oguri M, et al: Association of a polymorphism of BTN2A1 with dyslipidemia in East Asian populations. Exp Ther Med. 2:745–749. 2011.PubMed/NCBI
14	Ogg SL, Weldon AK, Dobbie L, Smith AJ and Mather IH: Expression of butyrophilin (Btn1a1) in lactating mammary gland is essential for the regulated secretion of milk-lipid droplets. Proc Natl Acad Sci USA. 101:10084–10089. 2004. View Article : Google Scholar : PubMed/NCBI
15	Arnett HA, Escobar SS and Viney JL: Regulation of costimulation in the era of butyrophilins. Cytokine. 46:370–375. 2009. View Article : Google Scholar : PubMed/NCBI
16	Oguri M, Kato K, Yoshida T, et al: Association of a genetic variant of BTN2A1 with metabolic syndrome in East Asian populations. J Med Genet. 48:787–792. 2011. View Article : Google Scholar : PubMed/NCBI
17	Khovidhunkit W, Kim MS, Memon RA, et al: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 45:1169–1196. 2004. View Article : Google Scholar : PubMed/NCBI
18	Esteve E, Ricart W and Frenándes-Real JM: Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 24:16–31. 2005. View Article : Google Scholar : PubMed/NCBI
19	Gallin JI, Kaye D and O’Leary WM: Serum lipids in infection. N Engl J Med. 281:1081–1086. 1969. View Article : Google Scholar : PubMed/NCBI
20	Sammalkorpi K, Valtonen V, Kerttula Y, Nikkilä E and Taskinen MR: Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 37:859–865. 1988. View Article : Google Scholar : PubMed/NCBI
21	Chen X, Xun K, Chen L and Wang Y: TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct. 27:407–416. 2009. View Article : Google Scholar : PubMed/NCBI
22	McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al: Inflammation impairs reverse cholesterol transport in vivo. Circulation. 119:1135–1145. 2009. View Article : Google Scholar : PubMed/NCBI
23	Reiss AB: Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep. 11:255–260. 2009. View Article : Google Scholar : PubMed/NCBI